Oryzon Genomics SA (id:4763 ORY)
1.52 EUR
Opening hours: 09:00 - 17:30 (Central European Standard Time: 12/24/2024 5:05:07 PM)
Exchange open, closes in 24 minutes
3.00 EUR (3.00%)
-8.00 EUR (-8.00%)
-7.44 EUR (-7.44%)
-17.32 EUR (-17.32%)
-25.04 EUR (-25.04%)
-46.55 EUR (-46.55%)
-66.19 EUR (-66.19%)
About Oryzon Genomics SA
Market Capitalization 98.44M
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
| Headquarters (address) |
Sant Ferran 74 Cornellà de Llobregat 08940 Spain |
| Phone | 34 93 515 13 13 |
| Website | https://www.oryzon.com |
| Employees | 46 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ORY |
| Exchange | Madrid Stock Exchange |
| Currency | EUR |
| 52 week range | 1.49 - 2.38 |
| Market Capitalization | 98.44M |
| P/E trailing | -27.85 |
| P/E forward | -9.11 |
| Price/Sale | 6.22 |
| Price/Book | 1.15 |
| Beta | 3.00 |
| EPS | 5.00 |
| EPS Spain (ID:221, base:143) | 3.00 |